Key information
Chief Investigator/Principal Investigator: Professor Sarah Fidler
Sponsor: Imperial College London
Trial Physician: Dr Ming Lee
Research Nurse: Mr Euan Sutherland
Phone: 020 3312 6499
The RIO study is looking at whether a new type of treatment called the monoclonal broadly neutralising antibodies (‘bNAbs’) can keep viral load undetectable without antiretroviral treatment (ART). This will involve asking all patients to stop ART for a short time
The study will measure how long viral load stays undetectable in a blood test without ART. It will also look at what happens to the HIV virus and immune system in blood samples. When virus becomes detectable in a blood test (‘viral rebound’) you will be asked to re-start your ART.
RIO is funded by the Bill & Melinda Gates Foundation. Imperial College London is the trial Sponsor, and the trial is coordinated by Imperial College London, the University of Oxford, and The Rockefeller University.
We have now closed to recruitment to this phase of the trial. We recruited 68 participants and would like to thank all the patients and clinical research partners for all their effort to make it this far.
We are now preparing to open a new phase to RIO and we will update with more information in the next coming months!
Please visit the RIO Trial website or the Health Research Authority RIO web page for more information.